ReviewClinical reviews in allergy & immunology2026
Regulatory B Cells at the Crossroads of Epigenetic Control and Immune Homeostasis.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- B-cells in breast cancer: current insights and challenges.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Regulatory B cells (Bregs) cooperate with FOXP3⁺ regulatory T cells (Tregs) to maintain immune tolerance. Among diverse Breg subsets, IL-10⁺ Bregs are the best-defined mediators of suppression across autoimmunity and cancer. We synthesize evidence that histone deacetylases (HDACs) are the central epigenetic switch coupling cytokine and checkpoint signals to the Il10 locus, thereby programming Breg identity and stabilizing immunosuppression. Mechanistically, Blimp-1, STAT3, and c-Maf integrate environmental cues (e.g., LPS, IL-21, TIM-1 ligation) with HDAC-directed chromatin accessibility, while BACH2 and HDAC3 restrain Prdm1 to gate plasmablast-like Breg differentiation. We outline how this HDAC–IL-10 module coordinates Breg–Treg crosstalk (CD40/CD40L, PD-1/PD-L1, TIGIT, adenosinergic CD39/CD73) to suppress Th1/Th17 effectors. Disease context dictates outcome: Breg deficits fuel autoimmunity, whereas Breg expansion/reprogramming in tumors dampens cytotoxic immunity (PD-L1⁺, VISTA⁺, IL-35⁺ Bregs). We propose a framework for precision epigenetic modulation: enhancing HDAC-sensitive Breg programs to restore tolerance in autoimmunity, and disrupting tumor-skewed Breg circuits (PD-L1/VISTA, IL-35/STAT3, adenosine metabolism) to improve cancer immunotherapy. This perspective unifies Breg heterogeneity under a tractable axis—HDAC-tuned IL-10 chromatin—and highlights clinically actionable levers at the interface of epigenetics and immune regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.